Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...

Plus: Blue Origin and SpaceX launch big rockets, how magnets could guide lasers to make better computers, how to best work ...

Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...

$540 $319 for your first year Make up your own mind. Build robust opinions on the FT's trusted journalism. Offer available until 27 February 2025. Then $75 per month. Complete digital access to ...

The Financial Times today cited sources as saying that OpenAI Chief Executive Sam Altman is participating in the investment. He previously provided the initial $180 million funding round that helped ...

OpenAI says it trained a new AI model called GPT-4b micro with Retro Biosciences, a longevity science startup trying to ...

OpenAI has created a ChatGPT model called GPT-4b micro for Retro Biosciences, a longevity research company - here's what it ...

OpenAI’s new model, called GPT-4b micro, was trained to suggest ways to re-engineer the protein factors to increase their ...

OpenAI's GPT-4b micro, in partnership with Retro Biosciences, aims to extend human lifespan by reengineering proteins.

OpenAI, the leading artificial intelligence (AI) lab, has trained a new AI model known as GPT-4b micro in collaboration with ...

Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...